Formulation and Evaluation of Transdermal Patches Containing BGP-15
Pharmaceutics · 27.12.2023 · 16 (1) · 36
DOI: 10.3390/pharmaceutics16010036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.12.2023. Verfasst von Ildikó Bácskay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Culture and Innovation of Hungary, Ministry for Innovation and Technology, European Union and the European Regional Development Fund.
Abstract (Originalsprache)
BGP-15 is an active ingredient with many advantages, e.g., beneficial cardiovascular and anti-inflammatory effects. The transdermal administration of BGP-15 has great potential, which has not been investigated yet, despite the fact that it is a non-invasive and safe form of treatment. The aim of our study was to formulate transdermal patches containing BGP-15 and optimize the production with the Box–Behnken design of experiment. The most optimal formulation was further combined with penetration enhancers to improve bioavailability of the active ingredient, and the in vitro drug release and in vitro permeation of BGP-15 from the patches were investigated. FTIR spectra of BGP-15, the formulations and the components were also studied. The most optimal formulation based on the tested parameters was dried for 24 h, with 67% polyvinyl alcohol (PVA) content and low ethanol content. The selected penetration enhancer excipients were not cytotoxic on HaCaT cells. The FTIR measurements and SEM photography proved the compatibility of the active substance and the vehicle; BGP-15 was present in the polymer matrix in dissolved form. The bioavailability of BGP-15 was most significantly enhanced by the combination of Transcutol and Labrasol. The in vitro permeation study confirmed that the formulated patches successfully enabled the transdermal administration of BGP-15.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
- Institute of Healthcare Industry, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
- Faculty of Engineering, University of Debrecen, Ótemető Utca 2-4, 4028 Debrecen, Hungary.
ORCID-Profile: Ildikó Bácskay, István Budai, Zoltán Ujhelyi, Dóra Kósa, Ádám Haimhoffer, Ágota Pető
Förderung
- Ministry of Culture and Innovation of Hungary
- Ministry for Innovation and Technology
- European Union and the European Regional Development Fund
- National Excellence Program of the Ministry for Innovation and Technology
Zitieren
APA
Bácskay, I., Hosszú, Z., Budai, I., Ujhelyi, Z., Fehér, P., Kósa, D., Haimhoffer, Á., & Pető, Á. (2023). Formulation and Evaluation of Transdermal Patches Containing BGP-15. Pharmaceutics, 16(1), 36. https://doi.org/10.3390/pharmaceutics16010036
Vancouver
Bácskay I, Hosszú Z, Budai I, Ujhelyi Z, Fehér P, Kósa D, et al. Formulation and Evaluation of Transdermal Patches Containing BGP-15. Pharmaceutics. 2023;16(1):36. doi:10.3390/pharmaceutics16010036
BibTeX
@article{Bcskay2023,
author = {Bácskay, Ildikó and Hosszú, Zsolt and Budai, István and Ujhelyi, Zoltán and Fehér, Pálma and Kósa, Dóra and Haimhoffer, Ádám and Pető, Ágota},
title = {Formulation and Evaluation of Transdermal Patches Containing BGP-15},
journal = {Pharmaceutics},
year = {2023},
volume = {16},
number = {1},
pages = {36},
doi = {10.3390/pharmaceutics16010036}
}
EUVIMED